Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis

Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb D Michaud, Ted R Mikuls, Andreas Reimold, David H. Collier, George J. Joseph, David J. Harrison, Brian C. Sauer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: The purpose of this study was to evaluate clinical outcomes and drug/administration costs of treatment with tumor necrosis factor inhibitor (TNFi) agents in US veterans with rheumatoid arthritis (RA) initiating TNFi therapy. The analysis compared patients initiating and continuing a single TNFi with patients who subsequently switched to a different TNFi. Methods: Data from patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry who initiated treatment with adalimumab, etanercept, or infliximab from 2003 to 2010 were analyzed. Outcomes included duration of therapy, Disease Activity Score based on 28 joints (DAS28), and direct drug and drug administration costs. Results: Of 563 eligible patients, 262 initiated a single TNFi therapy, 142 restarted their initial TNFi after a ≥90-day gap in treatment (interrupted therapy), and 159 switched to a different TNFi. Patients who switched had higher mean DAS28 before starting TNFi therapy than patients with single or interrupted therapy: 5.3 vs 4.5 or 4.6, respectively. Mean duration of the first course was 34.3 months for single therapy, 18.3 months for interrupted therapy, and 17.7 months for switched therapy. Mean post-treatment DAS28 was highest for patients who switched TNFi. Mean annualized costs for first course were $13,800 for single therapy, $13,200 for interrupted therapy, and $14,200 for switched therapy; mean annualized costs for second course were $12,800 for interrupted therapy and $15,100 for switched therapy. Conclusion: Patients who switched TNFi had higher pre-treatment DAS28 and higher overall costs than patients who received the same TNFi as either single or interrupted therapy. Funding: This research was funded by Immunex Corp., a fully owned subsidiary of Amgen Inc., and by VA HSR&D Grant SHP 08-172.

Original languageEnglish (US)
Pages (from-to)1347-1359
Number of pages13
JournalAdvances in Therapy
Volume33
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Veterans
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Costs and Cost Analysis
Therapeutics
Drug Costs

Keywords

  • Adalimumab
  • Biologics
  • Cost
  • Etanercept
  • Infliximab
  • Rheumatoid arthritis
  • Rheumatology
  • Switching
  • Tumor necrosis factor
  • Veterans affairs

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. / Cannon, Grant W.; DuVall, Scott L.; Haroldsen, Candace L.; Caplan, Liron; Curtis, Jeffrey R.; Michaud, Kaleb D; Mikuls, Ted R; Reimold, Andreas; Collier, David H.; Joseph, George J.; Harrison, David J.; Sauer, Brian C.

In: Advances in Therapy, Vol. 33, No. 8, 01.08.2016, p. 1347-1359.

Research output: Contribution to journalArticle

Cannon, GW, DuVall, SL, Haroldsen, CL, Caplan, L, Curtis, JR, Michaud, KD, Mikuls, TR, Reimold, A, Collier, DH, Joseph, GJ, Harrison, DJ & Sauer, BC 2016, 'Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis', Advances in Therapy, vol. 33, no. 8, pp. 1347-1359. https://doi.org/10.1007/s12325-016-0371-0
Cannon, Grant W. ; DuVall, Scott L. ; Haroldsen, Candace L. ; Caplan, Liron ; Curtis, Jeffrey R. ; Michaud, Kaleb D ; Mikuls, Ted R ; Reimold, Andreas ; Collier, David H. ; Joseph, George J. ; Harrison, David J. ; Sauer, Brian C. / Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. In: Advances in Therapy. 2016 ; Vol. 33, No. 8. pp. 1347-1359.
@article{c2faa064d8b04e219f610c5d24d67923,
title = "Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis",
abstract = "Introduction: The purpose of this study was to evaluate clinical outcomes and drug/administration costs of treatment with tumor necrosis factor inhibitor (TNFi) agents in US veterans with rheumatoid arthritis (RA) initiating TNFi therapy. The analysis compared patients initiating and continuing a single TNFi with patients who subsequently switched to a different TNFi. Methods: Data from patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry who initiated treatment with adalimumab, etanercept, or infliximab from 2003 to 2010 were analyzed. Outcomes included duration of therapy, Disease Activity Score based on 28 joints (DAS28), and direct drug and drug administration costs. Results: Of 563 eligible patients, 262 initiated a single TNFi therapy, 142 restarted their initial TNFi after a ≥90-day gap in treatment (interrupted therapy), and 159 switched to a different TNFi. Patients who switched had higher mean DAS28 before starting TNFi therapy than patients with single or interrupted therapy: 5.3 vs 4.5 or 4.6, respectively. Mean duration of the first course was 34.3 months for single therapy, 18.3 months for interrupted therapy, and 17.7 months for switched therapy. Mean post-treatment DAS28 was highest for patients who switched TNFi. Mean annualized costs for first course were $13,800 for single therapy, $13,200 for interrupted therapy, and $14,200 for switched therapy; mean annualized costs for second course were $12,800 for interrupted therapy and $15,100 for switched therapy. Conclusion: Patients who switched TNFi had higher pre-treatment DAS28 and higher overall costs than patients who received the same TNFi as either single or interrupted therapy. Funding: This research was funded by Immunex Corp., a fully owned subsidiary of Amgen Inc., and by VA HSR&D Grant SHP 08-172.",
keywords = "Adalimumab, Biologics, Cost, Etanercept, Infliximab, Rheumatoid arthritis, Rheumatology, Switching, Tumor necrosis factor, Veterans affairs",
author = "Cannon, {Grant W.} and DuVall, {Scott L.} and Haroldsen, {Candace L.} and Liron Caplan and Curtis, {Jeffrey R.} and Michaud, {Kaleb D} and Mikuls, {Ted R} and Andreas Reimold and Collier, {David H.} and Joseph, {George J.} and Harrison, {David J.} and Sauer, {Brian C.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s12325-016-0371-0",
language = "English (US)",
volume = "33",
pages = "1347--1359",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "8",

}

TY - JOUR

T1 - Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis

AU - Cannon, Grant W.

AU - DuVall, Scott L.

AU - Haroldsen, Candace L.

AU - Caplan, Liron

AU - Curtis, Jeffrey R.

AU - Michaud, Kaleb D

AU - Mikuls, Ted R

AU - Reimold, Andreas

AU - Collier, David H.

AU - Joseph, George J.

AU - Harrison, David J.

AU - Sauer, Brian C.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Introduction: The purpose of this study was to evaluate clinical outcomes and drug/administration costs of treatment with tumor necrosis factor inhibitor (TNFi) agents in US veterans with rheumatoid arthritis (RA) initiating TNFi therapy. The analysis compared patients initiating and continuing a single TNFi with patients who subsequently switched to a different TNFi. Methods: Data from patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry who initiated treatment with adalimumab, etanercept, or infliximab from 2003 to 2010 were analyzed. Outcomes included duration of therapy, Disease Activity Score based on 28 joints (DAS28), and direct drug and drug administration costs. Results: Of 563 eligible patients, 262 initiated a single TNFi therapy, 142 restarted their initial TNFi after a ≥90-day gap in treatment (interrupted therapy), and 159 switched to a different TNFi. Patients who switched had higher mean DAS28 before starting TNFi therapy than patients with single or interrupted therapy: 5.3 vs 4.5 or 4.6, respectively. Mean duration of the first course was 34.3 months for single therapy, 18.3 months for interrupted therapy, and 17.7 months for switched therapy. Mean post-treatment DAS28 was highest for patients who switched TNFi. Mean annualized costs for first course were $13,800 for single therapy, $13,200 for interrupted therapy, and $14,200 for switched therapy; mean annualized costs for second course were $12,800 for interrupted therapy and $15,100 for switched therapy. Conclusion: Patients who switched TNFi had higher pre-treatment DAS28 and higher overall costs than patients who received the same TNFi as either single or interrupted therapy. Funding: This research was funded by Immunex Corp., a fully owned subsidiary of Amgen Inc., and by VA HSR&D Grant SHP 08-172.

AB - Introduction: The purpose of this study was to evaluate clinical outcomes and drug/administration costs of treatment with tumor necrosis factor inhibitor (TNFi) agents in US veterans with rheumatoid arthritis (RA) initiating TNFi therapy. The analysis compared patients initiating and continuing a single TNFi with patients who subsequently switched to a different TNFi. Methods: Data from patients enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry who initiated treatment with adalimumab, etanercept, or infliximab from 2003 to 2010 were analyzed. Outcomes included duration of therapy, Disease Activity Score based on 28 joints (DAS28), and direct drug and drug administration costs. Results: Of 563 eligible patients, 262 initiated a single TNFi therapy, 142 restarted their initial TNFi after a ≥90-day gap in treatment (interrupted therapy), and 159 switched to a different TNFi. Patients who switched had higher mean DAS28 before starting TNFi therapy than patients with single or interrupted therapy: 5.3 vs 4.5 or 4.6, respectively. Mean duration of the first course was 34.3 months for single therapy, 18.3 months for interrupted therapy, and 17.7 months for switched therapy. Mean post-treatment DAS28 was highest for patients who switched TNFi. Mean annualized costs for first course were $13,800 for single therapy, $13,200 for interrupted therapy, and $14,200 for switched therapy; mean annualized costs for second course were $12,800 for interrupted therapy and $15,100 for switched therapy. Conclusion: Patients who switched TNFi had higher pre-treatment DAS28 and higher overall costs than patients who received the same TNFi as either single or interrupted therapy. Funding: This research was funded by Immunex Corp., a fully owned subsidiary of Amgen Inc., and by VA HSR&D Grant SHP 08-172.

KW - Adalimumab

KW - Biologics

KW - Cost

KW - Etanercept

KW - Infliximab

KW - Rheumatoid arthritis

KW - Rheumatology

KW - Switching

KW - Tumor necrosis factor

KW - Veterans affairs

UR - http://www.scopus.com/inward/record.url?scp=84976386638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976386638&partnerID=8YFLogxK

U2 - 10.1007/s12325-016-0371-0

DO - 10.1007/s12325-016-0371-0

M3 - Article

VL - 33

SP - 1347

EP - 1359

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 8

ER -